Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis
International Immunopharmacology · 2023-06 · 119 · 110294
DOI: 10.1016/j.intimp.2023.110294 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-06. Verfasst von Bahare Niknam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Wharton Jelly, Exosomes, MicroRNAs, Mesenchymal Stem Cells. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Iran National Science Foundation, Shaheed Beheshti University of Medical Sciences Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences.
Abstract (Originalsprache)
BACKGROUND: Liver fibrosis is a significant challenge to global health that results in organ failure through inflammation and the release of fibrotic biomarkers. Due to the lack of effective treatments for liver fibrosis, anti-fibrotic and anti-inflammatory therapies are being developed. Since there has been an association between aberrant expression of miR-124 and liver disease progression, we investigated whether delivery of miR-124 through human Wharton's jelly mesenchymal stem cells derived-exosomes (hWJMSC-Exo) can improve liver fibrosis. METHODS: We established a 6-week carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis, then we administered hWJMSC-Exo and miR-124-3p-enriched exosomes (ExomiR-124) for three weeks. The extent of fibrosis and inflammation was assessed by histology, biochemistry, Real-time PCR, immunohistochemistry, and Enzyme-linked immunoassays (ELISA). The inflammatory status of the spleen was also investigated using flow cytometry. RESULTS: Based on the gene and protein expression measurement of IL-6, IL-17, TGF-β, STAT3, α-SMA, and COL1, In vivo administration of Exo and ExomiR-124 effectively reduce collagen accumulation and inhibition of inflammation. Regarding histopathology findings, the therapeutic effect of ExomiR-124 against liver fibrosis was significantly greater than hWJMSC-Exo. In addition, we found that Exo and ExomiR-124 was capable of phenotype switching of splenic monocytes from inflammatory Ly6Chi to restorative Ly6Clo. CONCLUSIONS: MSC-derived exosomes demonstrated anti-inflammatory effect via different aspects. Aside from the therapeutic approach, enrichment of exosomes as a nanocarrier by miR-124 revealed the down-regulation of STAT3, which plays a crucial role in liver fibrosis. The anti-inflammatory and anti-fibrotic properties of ExomiR-124 could be a promising option in liver fibrosis combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Basic and Molecular Epidemiology of Gastroin…
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences,…
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: kavehbaghai@gmail.com.
Förderung
- Iran National Science Foundation
- Shaheed Beheshti University of Medical Sciences Research Center for Gastroenterology and Liver Diseases
- Shahid Beheshti University of Medical Sciences
Zitieren
APA
Niknam, B., Baghaei, K., Mahmoud Hashemi, S., Hatami, B., Reza Zali, M., & Amani, D. (2023). Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis. International Immunopharmacology, 119, 110294. https://doi.org/10.1016/j.intimp.2023.110294
Vancouver
Niknam B, Baghaei K, Mahmoud Hashemi S, Hatami B, Reza Zali M, Amani D. Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis. International Immunopharmacology. 2023;119:110294. doi:10.1016/j.intimp.2023.110294
BibTeX
@article{Niknam2023,
author = {Niknam, Bahare and Baghaei, Kaveh and Mahmoud Hashemi, Seyed and Hatami, Behzad and Reza Zali, Mohammad and Amani, Davar},
title = {Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis},
journal = {International Immunopharmacology},
year = {2023},
volume = {119},
pages = {110294},
doi = {10.1016/j.intimp.2023.110294}
}
EUVIMED